Lilly Signs Back-to-Back Deals in MASH, Cancer

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals, and another for cancer therapies with Australia’s AdvanCell.